guselkumab (Tremfya)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7]

Indications

Contraindications

Dosage

  • start 100 mg SQ at 0 & 4 weeks, then
  • 100 mg SQ every 8 weeks

Adverse effects

  • no unexpected safety findings through 2 years[6]

Mechanism of action

Management

More general terms

References

  1. ↑ Brooks M FDA OKs Biologic Guselkumab (Tremfya) for Plaque Psoriasis Medscape. July 14, 2017 http://www.medscape.com/viewarticle/882947
    Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
    U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
  2. ↑ From The Medical Letter on Drugs and Therapeutics Guselkumab (Tremfya) for Psoriasis JAMA. 2017;318(24):2487-2488 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29279926 https://jamanetwork.com/journals/jama/article-abstract/2667061
  3. ↑ Puig L, Augustin M, Blauvelt A et al Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study. J Am Acad Dermatol. 2017 Oct 21. pii: S0190-9622(17)32581-1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29066271
  4. ↑ Langley RG, Tsai TF, Flavin S et al Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2017 Jun 21. [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/28635018
  5. ↑ 5.0 5.1 Mease PJ, Rahman P, Gottlieb AB et al Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1126-1136 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32178766
    Deodhar A, Helliwell PS, Boehncke WH et al Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF-alpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1115-1125 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32178765
  6. ↑ 6.0 6.1 6.2 Harris S Iain McInnes, FRCP, PhD, on the Long-Term Efficacy of Guselkumab in Patients With Psoriatic Arthritis. Efficacy maintained over 100 weeks, benefit-safety ratio favorable. MedPage Today January 14, 2022 https://www.medpagetoday.com/reading-room/acrr/psoriaticarthritis/96670
    McInnes IB, Rahman P, Gottlieb AB. Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis. Arthritis Rheumatol. 2021. Nov. 1 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34719872 https://onlinelibrary.wiley.com/doi/10.1002/art.42010
  7. ↑ 7.0 7.1 Medical Knowledge Self Assessment Program (MKSAP) 19 American College of Physicians, Philadelphia 2022
Retrieved from "https://aaushi.info/w/index.php?title=A54219&oldid=1173096"